Insmed Inc (INSM)vsNeurosense Therapeutics Ltd (NRSN)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
NRSN
Neurosense Therapeutics Ltd
$0.77
+5.48%
HEALTHCARE · Cap: $27.11M
Smart Verdict
WallStSmart Research — data-driven comparison
NRSN leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
NRSN
Avoid16
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : NRSN
NRSN has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : NRSN
The primary concerns for NRSN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while NRSN is a value play — different risk/reward profiles.
NRSN carries more volatility with a beta of 1.56 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
NRSN generates stronger free cash flow (-2,000), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 16/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Neurosense Therapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Neurosense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology firm focused on developing groundbreaking therapies for neurodegenerative diseases, with a primary emphasis on Parkinson's disease. Through its proprietary development platform, the company is actively advancing several therapeutic candidates in critical clinical trials, highlighting its dedication to addressing significant unmet needs in neurology. Led by an experienced management team and supported by strategic partnerships, Neurosense is well-positioned to provide innovative treatment solutions that enhance patient quality of life while establishing a strong foothold in the biopharmaceutical industry.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?